Physician

Anjali Bal

According to 2025 Medicare claims, Anjali Bal (NPI: 1164818910) practices rheumatology in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is RHEUMATIC DISEASE ASSOCIATES,LTD (NPI: 1235116344; TIN: 232003199) and primary practice location at 19090-1709.

Bal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 560 traditional Medicare patients, billed 49,880 HCPCS/CPT codes, and received $641,871 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,248 prescription claims across 305 beneficiaries totaling $304,815 in drug costs, led by Hydroxychloroquine Sulfate (Hydroxychloroquine Sulfate). 2017 DME data shows 12 claims. Open Payments data shows 97 records totaling $1,997. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $18,349 to $641,871. Similarly, Part D prescription costs have risen steadily, from $8,371 to $304,815. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	76	225	$18,349
2019	73	243	$18,566
2020	N/R	N/R	N/R
2021	62	343	$14,839
2022	470	35,356	$521,155
2023	665	68,344	$982,711
2024	560	49,880	$641,871

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	26	164	$8,371
2016	53	536	$28,129
2017	66	549	$23,857
2018	53	454	$25,615
2019	101	291	$169,157
2020	94	577	$349,684
2021	120	431	$312,899
2022	183	545	$131,879
2023	280	980	$161,442
2024	305	1,248	$304,815

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	12	$91
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	322	538	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	94	104	$67
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	157	253	$59
J0897	Injection, denosumab, 1 mg	120	8,340	$21
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	330	588	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	162	13,035	$5,196
Risedronate Sodium	Risedronate Sodium	31	2,598	$5,099
Febuxostat	Febuxostat	30	1,530	$3,773
Celecoxib	Celecoxib	35	1,950	$3,510
Methotrexate	Methotrexate Sodium	134	8,465	$3,130

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	97	$1,997	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anjali Bal?

Tedicare shows public-source Medicare data for Anjali Bal (NPI 1164818910), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anjali Bal have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anjali Bal?

Anjali Bal is linked to RHEUMATIC DISEASE ASSOCIATES,LTD (billing NPI 1235116344) in the available physician profile data.

Does Anjali Bal have Open Payments data?

Anjali Bal has 97 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.